Asparaginase-Based Therapy in Young and Older Adults With ALL: Leveraging the Pediatric Experience

Asparaginase-Based Therapy in Young and Older Adults With ALL: Leveraging the Pediatric Experience

Friday, December 10, 2021
Webinar -- 3:30 PM ET
https://www.clinicaloptions.com/ALLAtlanta2021Join1

Agenda

  • Welcome and Introduction
  • Background
  • Overview of ALL Management: Induction, Consolidation, and Maintenance Treatment Algorithms
  • Applying Lessons and Experience in Pediatric Patients to the Treatment of AYA and Adult Patients With ALL
  • Strategies to Increase Completion of Asparaginase Treatment
  • Panel Discussion

Faculty

Program Director
Wendy Stock, MD

Professor of Medicine
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Faculty
Emily Curran, MD

Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Faculty
Dan Douer, MD

Associate Professor of Medicine
Jane Anne Nohle Division of Hematology
Keck School of Medicine
University of Southern California
Los Angeles, California

Faculty
Scott Howard, MD, MSc

Professor
College of Nursing
The University of Tennessee Health Science Center
Memphis, Tennessee

Faculty
Stephen P. Hunger, MD

Chief, Division of Pediatric Oncology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging asparaginase therapies for treatment of acute lymphoblastic leukemia in young adolescent and adult patients.

Target Audience
This program is intended for hematologists/oncologists and other health professionals that care for patients with acute lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select asparaginase-based induction treatment for adolescent/young adult and adult patients, considering optimal dosing and treatment schedules
  • Identify clinical and silent hypersensitivity reactions to asparaginase therapies
  • Plan strategies to achieve continued and active asparaginase treatment including activity level testing and premedication
  • Integrate expert recommendations and available data on re-exposure of currently available asparaginase treatments or recombinant asparaginase formulations
  • Consider the data and clinical experience in pediatric patients to aid in treatment decisions for adolescent/young adult and adult patients

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.